TRAW
Traws Pharma, Inc.
Price Chart
Latest Quote
$0.80
-0.04 (-4.46%)
Current Price
| Previous Close | $0.84 |
| Open | $0.84 |
| Day High | $0.89 |
| Day Low | $0.80 |
| Volume | 307,079 |
Stock Information
| Shares Outstanding | 15.15M |
| Cash Equivalents | $3.13M |
| Revenue | $2.73M |
| Net Income | $-13.91M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $12.10M |
| EPS (TTM) | $-1.87 |
| Exchange | NCM |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $9.53M |
| Sales | $2.73M |
| Income | $-13.91M |
| Book/sh | $-0.07 |
| Cash/sh | $0.21 |
| Employees | 4 |
Financial Ratios
| Quick Ratio | 0.36 |
| Current Ratio | 0.43 |
Returns & Margins
| ROA | -90.09% |
| ROE | -5639.19% |
| Gross Margin | 100.00% |
| Operating Margin | -717.82% |
Ownership
| Insider Ownership | 9.44% |
| Institutional Ownership | 44.15% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -0.40 |
| P/S | 4.43 |
| P/B | -11.57 |
Analyst Data
| Recommendation | buy |
| Target Price | $8.00 |
Technical Indicators
| SMA20 | $1.34 |
| SMA50 | $1.44 |
| SMA200 | $1.87 |
| RSI | 16.67 |
| ATR | 0.1279 |
| Shares Float | 11.73M |
| Short Float | 10.71% |
| Short Ratio | 0.23 |
| Volatility | 1.45 |
| Rel Volume | 0.44 |
Performance History
| Week | -36.00% |
| Month | -54.55% |
| Quarter | -60.40% |
| 6 Months | -64.29% |
| YTD | -39.85% |
| Year | -50.92% |
| 3 Years | -97.12% |
| 5 Years | -99.55% |
| 10 Years | -100.00% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-17 | $0.80 | 316,100 |
| 2026-06-16 | $0.84 | 783,800 |
| 2026-06-15 | $0.76 | 4,894,300 |
| 2026-06-12 | $1.28 | 338,200 |
| 2026-06-11 | $1.27 | 268,100 |
| 2026-06-10 | $1.25 | 443,500 |
| 2026-06-09 | $1.31 | 295,800 |
| 2026-06-08 | $1.37 | 185,000 |
| 2026-06-05 | $1.37 | 354,200 |
| 2026-06-04 | $1.48 | 144,400 |
| 2026-06-03 | $1.45 | 224,900 |
| 2026-06-02 | $1.42 | 292,300 |
| 2026-06-01 | $1.47 | 351,400 |
| 2026-05-29 | $1.46 | 376,600 |
| 2026-05-28 | $1.52 | 429,000 |
| 2026-05-27 | $1.53 | 1,307,100 |
| 2026-05-26 | $1.58 | 572,900 |
| 2026-05-22 | $1.49 | 788,000 |
| 2026-05-21 | $1.49 | 927,200 |
| 2026-05-20 | $1.62 | 938,800 |
| 2026-05-19 | $1.59 | 482,200 |
| 2026-05-18 | $1.76 | 787,900 |
About Traws Pharma, Inc.
Traws Pharma, Inc., a clinical-stage biopharmaceutical company, develops small synthetic molecules for respiratory viral diseases and cancer. The company is developing investigational novel therapies for influenza and COVID-19 that are designed to address treatment resistance, such as TRX01 (Ratutrelvir), an inhibitor in development for the treatment of COVID-19; and Tivoxavir marboxil, an endonuclease inhibitor in development for the treatment of bird flu and seasonal influenza. It is also developing narazaciclib, a multi-targeted kinase inhibitor in solid tumors and hematological malignancies as a single agent or in combination with other anti-cancer therapies; and rigosertib, which is administered alone or in combination for investigation in various cancers. It has a license agreement with SymBio Pharmaceuticals Limited, Pint International SA, Viriom, Inc., Knight Therapeutics Inc., Specialised Therapeutics Asia Pte. Ltd., and Temple University. The company was formerly known as Onconova Therapeutics, Inc. and changed its name to Traws Pharma, Inc. in April 2024. Traws Pharma, Inc. was incorporated in 1998 and is headquartered in Newtown, Pennsylvania.
đ° Latest News
Traws Pharma Shares Slide After UK Regulator Postpones Influenza Study
InvestorsHub âĸ 2026-06-15T10:26:33Z
Why Did TRAW Stock Slump 28% After Hours?
Stocktwits âĸ 2026-06-13T00:07:37Z
Sector Update: Healthcare Stocks Lower Late Afternoon
MT Newswires âĸ 2026-05-08T19:58:23ZTraws Pharma, Inc. (TRAW) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?
Zacks âĸ 2026-04-20T13:55:01Z
Traws Pharma, Inc. Q4 2025 Earnings Call Summary
Moby âĸ 2026-04-16T12:30:00Z
Traws Pharma Inc (TRAW) Q4 2025 Earnings Call Highlights: A Turnaround Year with Significant ...
GuruFocus.com âĸ 2026-04-16T07:01:41ZhVIVO, Connecting Excellence, ACG Metals, Kodal Minerals, Ariana Resources, Sunda Energy
Proactive âĸ 2026-04-14T08:17:05Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | $2,790,000 | $226,000 | $226,000 | $226,000 |
| Operating Revenue | $2,790,000 | $226,000 | $226,000 | $226,000 |
| Expenses | ||||
| Total Expenses | $20,665,000 | $25,136,000 | $20,524,000 | $19,853,000 |
| Other Income Expense | $27,045,000 | $-141,613,000 | $1,350,000 | $663,000 |
| Other Non Operating Income Expenses | $478,000 | $289,000 | $1,350,000 | $663,000 |
| Operating Expense | $20,665,000 | $25,136,000 | $20,524,000 | $19,853,000 |
| General And Administrative Expense | $8,522,000 | $12,289,000 | $9,094,000 | $8,447,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $9,170,000 | $-166,523,000 | $-18,948,000 | $-18,964,000 |
| Normalized Income | $-17,397,000 | $-24,621,000 | $-18,948,000 | $-18,964,000 |
| Net Income From Continuing And Discontinued Operation | $9,170,000 | $-166,523,000 | $-18,948,000 | $-18,964,000 |
| Total Operating Income As Reported | $-17,875,000 | $-142,374,000 | $-20,298,000 | $-19,627,000 |
| Net Income Common Stockholders | $6,865,000 | $-54,674,000 | $-18,948,000 | $-18,964,000 |
| Net Income | $9,170,000 | $-166,523,000 | $-18,948,000 | $-18,964,000 |
| Net Income Including Noncontrolling Interests | $9,170,000 | $-166,523,000 | $-18,948,000 | $-18,964,000 |
| Net Income Continuous Operations | $9,170,000 | $-166,523,000 | $-18,948,000 | $-18,964,000 |
| Pretax Income | $9,170,000 | $-166,523,000 | $-18,948,000 | $-18,964,000 |
| Special Income Charges | $0 | $-117,464,000 | $0 | - |
| Operating Income | $-17,875,000 | $-24,910,000 | $-20,298,000 | $-19,627,000 |
| Per Share | ||||
| Diluted EPS | $0.82 | $-35.21 | $-22.57 | $-22.75 |
| Basic EPS | $0.83 | $-35.21 | $-22.57 | $-22.75 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-44,381,000 | $117,004,000 | $-20,282,000 | $-19,613,000 |
| Total Unusual Items | $26,567,000 | $-141,902,000 | $0 | - |
| Total Unusual Items Excluding Goodwill | $26,567,000 | $-141,902,000 | $0 | - |
| Reconciled Depreciation | $61,000 | $12,000 | $16,000 | $14,000 |
| EBITDA (Bullshit earnings) | $-17,814,000 | $-24,898,000 | $-20,282,000 | $-19,613,000 |
| EBIT | $-17,875,000 | $-24,910,000 | $-20,298,000 | $-19,627,000 |
| Diluted Average Shares | $8,376,380 | $1,552,685 | $839,554 | $836,329 |
| Basic Average Shares | $8,228,169 | $1,552,685 | $839,554 | $836,329 |
| Diluted NI Availto Com Stockholders | $6,865,000 | $-54,674,000 | $-18,948,000 | $-18,964,000 |
| Preferred Stock Dividends | $2,305,000 | $-111,849,000 | - | - |
| Gain On Sale Of Security | $26,567,000 | $-24,438,000 | - | - |
| Research And Development | $12,143,000 | $12,847,000 | $11,430,000 | $11,406,000 |
| Selling General And Administration | $8,522,000 | $12,289,000 | $9,094,000 | $8,447,000 |
| Other Gand A | $4,624,000 | $7,185,000 | $4,130,000 | $3,206,000 |
| Insurance And Claims | $837,000 | $860,000 | $985,000 | $1,295,000 |
| Salaries And Wages | $3,061,000 | $4,244,000 | $3,979,000 | $3,946,000 |
| Other Special Charges | - | $117,464,000 | - | - |
| Tax Provision | - | - | - | - |
Fetched: 2026-06-16
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $-3,156,000 | $-31,630,000 | $10,672,000 | $28,309,000 |
| Total Assets | $10,617,000 | $24,962,000 | $22,683,000 | $39,372,000 |
| Total Non Current Assets | $2,638,000 | $11,000 | $23,000 | $25,000 |
| Other Non Current Assets | $104,000 | $1,000 | $1,000 | $1,000 |
| Goodwill And Other Intangible Assets | $2,527,000 | $0 | - | - |
| Other Intangible Assets | $2,527,000 | - | - | - |
| Current Assets | $7,979,000 | $24,951,000 | $22,660,000 | $39,347,000 |
| Other Current Assets | $89,000 | $178,000 | $401,000 | $40,000 |
| Prepaid Assets | $276,000 | $1,670,000 | $1,420,000 | $521,000 |
| Receivables | $3,794,000 | $1,765,000 | $18,000 | $29,000 |
| Accounts Receivable | $3,794,000 | $1,765,000 | $18,000 | $29,000 |
| Cash Cash Equivalents And Short Term Investments | $3,820,000 | $21,338,000 | $20,821,000 | $38,757,000 |
| Cash And Cash Equivalents | $3,820,000 | $21,338,000 | $20,821,000 | $38,757,000 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $11,246,000 | $56,592,000 | $12,011,000 | $11,063,000 |
| Total Non Current Liabilities Net Minority Interest | $100,000 | $45,059,000 | $2,791,000 | $3,017,000 |
| Derivative Product Liabilities | $100,000 | $42,494,000 | $0 | - |
| Non Current Deferred Liabilities | $0 | $2,565,000 | $2,791,000 | $3,017,000 |
| Current Liabilities | $11,146,000 | $11,533,000 | $9,220,000 | $8,046,000 |
| Other Current Liabilities | $128,000 | - | - | - |
| Current Deferred Liabilities | $0 | $226,000 | $226,000 | $226,000 |
| Payables And Accrued Expenses | $10,082,000 | $11,042,000 | $7,992,000 | $6,633,000 |
| Payables | $5,653,000 | $8,186,000 | $5,619,000 | $3,860,000 |
| Accounts Payable | $5,653,000 | $8,186,000 | $5,619,000 | $3,860,000 |
| Equity | ||||
| Common Stock Equity | $-629,000 | $-31,630,000 | $10,672,000 | $28,309,000 |
| Total Equity Gross Minority Interest | $-629,000 | $-31,630,000 | $10,672,000 | $28,309,000 |
| Stockholders Equity | $-629,000 | $-31,630,000 | $10,672,000 | $28,309,000 |
| Gains Losses Not Affecting Retained Earnings | $6,000 | $-42,000 | $-23,000 | $-33,000 |
| Other Equity Adjustments | $6,000 | $-42,000 | $-23,000 | $-33,000 |
| Retained Earnings | $-639,984,000 | $-649,154,000 | $-482,631,000 | $-463,683,000 |
| Other | ||||
| Ordinary Shares Number | $9,067,774 | $3,650,731 | $840,136 | $837,039 |
| Share Issued | $9,067,774 | $3,650,731 | $840,136 | $837,039 |
| Tangible Book Value | $-3,156,000 | $-31,630,000 | $10,672,000 | $28,309,000 |
| Invested Capital | $-629,000 | $-31,630,000 | $10,672,000 | $28,309,000 |
| Working Capital | $-3,167,000 | $13,418,000 | $13,440,000 | $31,301,000 |
| Total Capitalization | $-629,000 | $-31,630,000 | $10,672,000 | $28,309,000 |
| Additional Paid In Capital | $639,259,000 | $617,530,000 | $493,317,000 | $491,816,000 |
| Capital Stock | $90,000 | $36,000 | $9,000 | $209,000 |
| Common Stock | $90,000 | $36,000 | $9,000 | $209,000 |
| Preferred Stock | $0 | $0 | $0 | $0 |
| Non Current Deferred Revenue | $0 | $2,565,000 | $2,791,000 | $3,017,000 |
| Current Deferred Revenue | $0 | $226,000 | $226,000 | $226,000 |
| Pensionand Other Post Retirement Benefit Plans Current | $936,000 | $265,000 | $1,002,000 | $1,187,000 |
| Current Accrued Expenses | $4,429,000 | $2,856,000 | $2,373,000 | $2,773,000 |
| Net PPE | $7,000 | $10,000 | $22,000 | $24,000 |
| Accumulated Depreciation | $-77,000 | $-74,000 | $-62,000 | $-46,000 |
| Gross PPE | $84,000 | $84,000 | $84,000 | $70,000 |
| Machinery Furniture Equipment | $84,000 | $84,000 | $84,000 | $70,000 |
| Treasury Shares Number | - | - | $0 | - |
Fetched: 2026-06-16
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-20,770,000 | $-29,792,000 | $-17,946,000 | $-16,294,000 |
| Operating Activities | ||||
| Operating Cash Flow | $-18,185,000 | $-29,792,000 | $-17,932,000 | $-16,294,000 |
| Cash Flow From Continuing Operating Activities | $-18,185,000 | $-29,792,000 | $-17,932,000 | $-16,294,000 |
| Operating Gains Losses | $-26,567,000 | $24,438,000 | - | - |
| Investing Activities | ||||
| Capital Expenditure | $-2,585,000 | - | $-14,000 | - |
| Investing Cash Flow | $-2,585,000 | $-3,648,000 | $-14,000 | $0 |
| Cash Flow From Continuing Investing Activities | $-2,585,000 | $-3,648,000 | $-14,000 | $0 |
| Financing Activities | ||||
| Issuance Of Capital Stock | $5,582,000 | $33,976,000 | $0 | $0 |
| Financing Cash Flow | $3,204,000 | $33,976,000 | $0 | $0 |
| Cash Flow From Continuing Financing Activities | $3,204,000 | $33,976,000 | $0 | $0 |
| Net Other Financing Charges | $-2,404,000 | - | - | - |
| Net Common Stock Issuance | $5,582,000 | $33,976,000 | $0 | $0 |
| Common Stock Issuance | $5,582,000 | $33,976,000 | $0 | $0 |
| Other | ||||
| End Cash Position | $3,820,000 | $21,338,000 | $20,821,000 | $38,757,000 |
| Beginning Cash Position | $21,338,000 | $20,821,000 | $38,757,000 | $55,070,000 |
| Effect Of Exchange Rate Changes | $48,000 | $-19,000 | $10,000 | $-19,000 |
| Changes In Cash | $-17,566,000 | $536,000 | $-17,946,000 | $-16,294,000 |
| Proceeds From Stock Option Exercised | $26,000 | $0 | - | $0 |
| Net Business Purchase And Sale | $0 | $-3,648,000 | $0 | - |
| Purchase Of Business | $0 | $-3,648,000 | $0 | - |
| Net Intangibles Purchase And Sale | $-2,585,000 | $0 | - | - |
| Purchase Of Intangibles | $-2,585,000 | $0 | - | - |
| Change In Working Capital | $-1,577,000 | $-6,573,000 | $-301,000 | $1,484,000 |
| Change In Other Working Capital | $-2,791,000 | $-226,000 | $-226,000 | $-226,000 |
| Change In Payables And Accrued Expense | $1,760,000 | $-4,573,000 | $1,174,000 | $1,931,000 |
| Change In Accrued Expense | $2,372,000 | $-5,219,000 | $-585,000 | $828,000 |
| Change In Payable | $-612,000 | $646,000 | $1,759,000 | $1,103,000 |
| Change In Account Payable | $-612,000 | $646,000 | $1,759,000 | $1,103,000 |
| Change In Prepaid Assets | $1,483,000 | $-27,000 | $-1,260,000 | $-229,000 |
| Change In Receivables | $-2,029,000 | $-1,747,000 | $11,000 | $-1,000 |
| Stock Based Compensation | $728,000 | $1,390,000 | $1,301,000 | $1,172,000 |
| Depreciation Amortization Depletion | $61,000 | $12,000 | $16,000 | $14,000 |
| Depreciation And Amortization | $61,000 | $12,000 | $16,000 | $14,000 |
| Gain Loss On Investment Securities | $-26,567,000 | $24,438,000 | - | - |
| Net Income From Continuing Operations | $9,170,000 | $-166,523,000 | $-18,948,000 | $-18,964,000 |
| Net PPE Purchase And Sale | - | $0 | $-14,000 | $0 |
| Purchase Of PPE | - | $0 | $-14,000 | $0 |
| Other Non Cash Items | - | $117,464,000 | - | - |
| Change In Other Current Assets | - | - | $0 | $9,000 |
Fetched: 2026-06-16